# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics   
9115 Hague Road   
Indianapolis, IN 46250   
Phone: (317) 521 - 3831   
Fax: (317) 521 -2324   
Contact Person: Kathie J. Goodwin   
Date Prepared: April $2 3 ^ { \mathsf { r d } }$ , 2010

# Device Name

Proprietary names: Tina-Quant Albumin Gen. 2

Common names: Albumin Gen. 2 assay

Regulation: 21 CFR 866.5040

Classification names: Albumin Immunological Test System

Product codes: DCF

# Device Description

The Tina-quant Albumin Gen. 2 assay employs an immunoturbidimetric test in which anti-albumin antibodies react with the antigen in the sample to form antigen/antibody complexes which, following agglutination are determined turbidimetrically.

# Intended use

Immunoturbidimetric assay for the quantitative, in vitro determination of albumin in human urine, serum, plasma and CSF on Roche/Hitachi cobas c systems.

# Indications for Use

The Tina-quant Albumin Gen. 2 assay is an immunoturbidimetric assay intended for the quantitative determination of albumin in serum, plasma, urine, and CSF on Roche/Hitachi cobas c systems. Measurement of albumin aids in the diagnosis of kidney and intestinal diseases.

# Substantial equivalence

The urine application of the Tina-quant Albumin Gen. 2 assay is substantially equivalent to the Hitachi Microalbumin urine assay. The Hitachi Microalbumin urine assay was cleared under K932950.

The Serum/plasma and CSF applications of the Tina-quant Albumin Gen. 2 assays are substantially equivalent to the Behring Nephelometric method cleared in K972929.

Substantial equivalence - comparison   

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">Tina-quant Albumin Gen. 2 AssayUrine Application</td><td colspan="1" rowspan="1">Predicate Device: HitachiMicroalbumin Urine Assay(K932950)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">In vitro test for the quantitativedetermination of albumin in humanurine, serum, plasma and CSF(albumin CSF/serum ratio) onRoche/Hitachi cobas c systems.</td><td colspan="1" rowspan="1">For the quantitative determination oflow levels of albumin in urine(Microalbumin, MAU).</td></tr><tr><td colspan="1" rowspan="1">Assay Protocol</td><td colspan="1" rowspan="1">Immunoturbidimetric</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">LabeledInstrumentPlatform</td><td colspan="1" rowspan="1">Roche/Hitachi cobas c analyzer cobas c501</td><td colspan="1" rowspan="1">Boehringer Mannheim/Hitachi 747analyzer</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">C.f.a.s. PUC</td><td colspan="1" rowspan="1">Microalbumin calibrators (included inkit)</td></tr><tr><td colspan="1" rowspan="1">CalibrationFrequency</td><td colspan="1" rowspan="1">Calibrate after reagent lot changeand as required following qualitycontrol procedures</td><td colspan="1" rowspan="1">Perform full calibration every twoweeks.</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Precinorm PUC and Precipath PUCorPrecinorm Protein and PrecipathProtein</td><td colspan="1" rowspan="1">Precinorm Albumin and PrecipathAlbumin</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">On-board in use:12 weeks at 2-8 Deg. C</td><td colspan="1" rowspan="1">On-board in use:4 weeks at 2-12 Deg. C</td></tr><tr><td colspan="2">Measuring c501: 12-400 mg/L</td><td>3 mg/L up to the value of the highest calibrator</td></tr><tr><td>Range</td><td>cobas c501:</td><td>Note: calibrator values were lot specific. In one representative lot, values (mg/L) were: Cal 3a: 0.0 Cal 3b: 10.5 Cal 3c: 62.6 Cal 3d: 154.0 Cal 3e: 347.0 Within-run (mg/L):</td></tr><tr><td rowspan="2">Precision</td><td>Repeatability (Within-run) (mg/L): Mean = 30.7, SD = 0.2, CV = 0.8% Mean = 108, SD = 1, CV = 0.7% Mean = 14.3, SD = 0.2, CV = 1.6% Mean = 252 mg/L, SD = 4, CV = 1.6%</td><td>Mean = 9.0, SD = 0.29, CV = 3.2% Mean = 22.1, SD = 0.30, CV = 1.4% Mean = 81.1, SD = 0.67, CV = 0.8% Total (mg/L):</td></tr><tr><td>Intermediate Precision (Total) (mg/L): Mean = 31.2, SD = 0.5, CV = 1.7% Mean = 105, SD = 1, CV = 1.2% Mean = 13.6, SD = 0.4, CV = 2.8% Mean = 60.6, SD = 1.4, CV = 2.3%</td><td>Mean = 9.0, SD = 0.92, CV = 10.1% Mean = 22.1, SD = 1.15, CV = 5.2% Mean = 81.1, SD = 0.78. CV = 1.0%</td></tr><tr><td>Analytical Sensitivity</td><td>Limit of Blank (LoB) =2 mg/L Limit of Detection (LoD) =3 mg/L Limit of Quantitation (LoQ) =12 mg/L</td><td>Lower Detection Limit = 3 mg/L No interference was observed from 18</td></tr><tr><td>Analytical Specificity</td><td>No interference was found at common therapeutic concentrations using common drug panels. Due to the antigen excess check reagent R3, no unflagged high-dose hook effect will occur up to an albumin concentration of 40000 mg/L.</td><td>common drugs.</td></tr></table>

Tina-quant Albumin Gen. 2 Assay   

<table><tr><td rowspan=1 colspan=1>Interferences</td><td rowspan=1 colspan=1>Criterion: Recovery within ± 10%Icterus: no significant interference upto an I index of 50 (approximateconjugated bilirubin concentration: 50mg/dL)Hemolysis: No significant interferenceup to an H index of 400 (approximatehemoglobin concentration: 400 mg/dL)No interference by acetone ≤ 60mmol/L, ammonia chloride ≤0.11mol/L, calcium ≤40 mmol/L, Creatinine≤0.18 mol/L, γ-globulin ≤500 mg/L,glucose ≤0.19 mol/L, urea ≤0.8 mol/L,uric acid ≤5.95 mmol/L andurobilinogen ≤378 umol/L.</td><td rowspan=1 colspan=1>No significant interference observed fromcalcium levels up to 100 mg/dL.Icterus: no significant interference frombilirubin up to 25 mg/dL.Hemolysis: Hemoglobin levels &gt;300mg/dL cause significant positiveinterference.Lipemia (Intralipid): No significantinterference up to an L index of 200.There is poor correlation between the Lindex (corresponds to turbidity) andtriglyceride concentration.</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>2d morning urine:Adults:&lt;20 mg albumin/g creatinine or&lt;2.26 g albumin/mol creatinineChildren (3-5 years):&lt;20 mg/L albumin&lt;37 mg albumin/g creatinine24 hour urine:&lt;20 mg/L&lt;30 mg/24 h</td><td rowspan=1 colspan=1>2nd morning urine:Adults:sameChildren (3-5 years):same24 hour urine:Microalbuminuria: 30-300 mgalbumin/24 hr</td></tr><tr><td rowspan=1 colspan=1>MethodComparisons</td><td rowspan=1 colspan=2>A comparison of the Roche Tina-quant Albumin Gen. 2 assay on the c501analyzer(x) with the Hitachi Microalbumin assay on the Hitachi 917 analyzer(K953239) (y) gave the following correlation:Passing Bablock                  Linear Regressiony = 1.023x + 3.64 mg/L        y = 1.028x - 4.13 mg/Lτ= 0.984                           r= 0.999n = 125Sample concentrations were between 12.3 and 386 mg/L</td></tr></table>

Substantial equivalence - comparison   

<table><tr><td rowspan=1 colspan=1>conparison</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Tina-quant Albumin Gen. 2 AssaySerum/Plasma Application</td><td rowspan=1 colspan=1>Predicate Device: Behring NAntiserum to Human AlbuminAssay (K972929)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In vitro test for the quantitativedetermination of albumin in humanurine, serum, plasma and CSF(albumin CSF/serum ratio) onRoche/Hitachi cobas c systems.</td><td rowspan=1 colspan=1>In vitro diagnostic reagent for thequantitative determination ofalbumin, prealbumin (transthyretin)and retinol-binding protein (RbP) inhuman serum as well as of albuminin human urine and cerebrospinalfluid (CSF) using the BN Systems.</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Immunoturbidimetric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>SerumPlasma: Li-heparin and K2-EDTA</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>LabeledInstrumentPlatform</td><td rowspan=1 colspan=1>Roche/Hitachi cobas c analyzer -cobas c501</td><td rowspan=1 colspan=1>BN Systems</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>C.f.a.s. PUC</td><td rowspan=1 colspan=1>N Protein Standard SL (human)</td></tr><tr><td rowspan=1 colspan=1>Calibrationfrequency</td><td rowspan=1 colspan=1>Full calibration is recommended afterreagent lot change and as requiredfollowing quality control procedures.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Precinorm PUC and Precipath PUCorPrecinorm Protein and PrecipathProtein</td><td rowspan=1 colspan=1>N/T Protein Controls SL/L, M and HorN/T Protein Control LC</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>c501:3- 101 g/L</td><td rowspan=1 colspan=1>Reference curves are generated bymulti-point calibration. Serialdilutions on N Protein Standard SLare automatically prepared by theinstrument using N Diluent.</td></tr></table>

Tina-quant Albumin Gen. 2 Assay   

<table><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>cobas c501:Repeatability (Within-run) (mg/L):Mean = 39.9, SD = 0.5, CV = 1 .2%Mean = 66.6, SD = 1.4, CV = 1.2%Mean = 27.6, SD = 0.4, CV = 1.3%Mean = 62.5 mg/L, SD = 0.9, CV =1.5%Intermediate Precision (Total) (mg/L):Mean = 42.3, SD = 0.9, CV = 2.0%Mean = 70.5, SD = 1.6, CV = 2.2%Mean = 7.78, SD = 0.74, CV = 9.5%Mean = 36.2, SD = 0.7, CV = 2.1%</td><td rowspan=1 colspan=1>Intra-assay (g/L):Mean: 46.5; CV: 4.3%Inter-assay (g/L)Mean: 44.7; CV: 4.4%</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=1>Limit of Blank (LoB) = 1 g/dLLimit of Detection (LoD) = 2 g/dLLimit of Quantitation (LoQ) = 3 g/dL</td><td rowspan=1 colspan=1>Established by the lower limit of thereference curve and dependstherefore upon the concentrations ofthe proteins in the N ProteinStandard SL.</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSpecificity</td><td rowspan=1 colspan=1>No interference was found at commontherapeutic concentrations usingcommon drug panels.</td><td rowspan=1 colspan=1>No interference from commonly useddrugs is known.</td></tr><tr><td rowspan=1 colspan=1>Interferences</td><td rowspan=1 colspan=1>Criterion: Recovery within ± 10%Icterus: no significant interference up toan I index of 60 (approximate conjugatedbilirubin concentration: 60 mg/dL)Hemolysis: No significant interferenceup to an H index of 1000 (approximatehemoglobin concentration: 1000 mg/dL)Lipemia: No significant interference upto an L index of 1500 (approximateIntralipid concentration: 1500 mg/dL).There is poor correlation between theIntralipid concentration (corresponds toturbidity) and triglycerides concentration.Rheumatoid factors ≤ 1200 IU/mL do notinterfere.</td><td rowspan=1 colspan=1>Turbidity and particles in the samplemay interfere with the determination.Therefore, samples containing particlesmust be centrifuged prior to testing.Bovine serum albumin in the sample(e.g. control sample) may disturb thedetermination.</td></tr></table>

Tina-quant Albumin Gen. 2 Assay

<table><tr><td>Expected Values</td><td>Reference Range Study: Adults: 3.56-4.61 g/dL Consensus Values: Adults: 3.5 - 5.2 g/dL Reference Intervals according to Tietz: Newborns 0-4d: 2.8 - 4.4 g/dL Children 4d-14yr: 3.8 - 5.4 g/dL Children 14-18yr: 3.2 - 4.5 g/dL</td><td>Adults: 35.0 - 52.0 g/L</td></tr><tr><td rowspan="3">Method Comparison</td><td colspan="2">A comparison of the Roche Tina-quant Albumin Gen. 2 assay on the cobas c501 analyzer(x) with the nephelometric Albumin test gave the following correlation:</td></tr><tr><td>Passing Bablock Linear Regression y = -0.1320 + 0.9600x τ= 0.919 r = 0.993 n=77</td><td>y = -0.0095 + 0.9572x</td></tr><tr><td colspan="2">Sample concentrations were between 5.70 and 100 g/L</td></tr></table>

Substantial equivalence - comparison

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Tina-quant Albumin Gen. 2 AssayCSF Application</td><td rowspan=1 colspan=1>Predicate Device: Behring NAntiserum to Human AlbuminAssay (K972929)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In vitro test for the quantitativedetermination of albumin in humanurine, serum, plasma and CSF(albumin CSF/serum ratio) onRoche/Hitachi cobas c systems.</td><td rowspan=1 colspan=1>In vitro diagnostic reagent for thequantitative determination ofalbumin, prealbumin (transthyretin)and retinol-binding protein (RbP) inhuman serum as well as of albuminin human urine and cerebrospinalfluid (CSF) using the BN Systems</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Immunoturbidimetric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>LabeledInstrumentPlatform</td><td rowspan=1 colspan=1>Roche/Hitachi analyzer — cobas c501</td><td rowspan=1 colspan=1>BN Systems</td></tr></table>

Page 7 of 9

Tina-quant Albumin Gen. 2 Assay   

<table><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>C.f.a.s. PAC</td><td rowspan=1 colspan=1>N Protein Standard SL (human)</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Commercially available control</td><td rowspan=1 colspan=1>N/T Protein Controls SL/L, M and HorN/T Protein Control LC</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>c501:95 - 3000 mg/L</td><td rowspan=1 colspan=1>Reference curves are generated bymulti-point calibration. Serialdilutions on N Protein Standard SLare automatically prepared by theinstrument using N Diluent.</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>Repeatability (Within-run) (mg/L):Mean = 99.2, SD = 1.4, CV = 1.4%Mean = 174, SD = 3, CV = 1.7%Mean = 383, SD = 4, CV = 1.0%Mean = 454 mg/L, SD = 4, CV =0.8%Intermediate Precision (Total) (mg/L):Mean = 91.0, SD=2.9, CV = 3.2%Mean = 389, SD = 7, CV = 1.7%Mean = 166, SD = 4, CV = 2.3%Mean = 366, SD = 5, CV = 1.3%</td><td rowspan=1 colspan=1>Not specified for CSF</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=1>Limit of Blank (LoB) = 20 mg/LLimit of Detection (LoD) = 36 mg/LLimit of Quantitation (LoQ) = 95 mg/L</td><td rowspan=1 colspan=1>Established by the lower limit of thereference curve and dependstherefore upon the concentrations ofthe proteins in the N ProteinStandard SL.</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSpecificity</td><td rowspan=1 colspan=1>No interference was found at commontherapeutic concentrations usingcommon drug panels.</td><td rowspan=1 colspan=1>No interference from commonly useddrugs is known.</td></tr></table>

Tina-quant Albumin Gen. 2 Assay

<table><tr><td rowspan=1 colspan=1>Interferences</td><td rowspan=1 colspan=1>Criterion: Recovery within ± 10%Hemolysis: No significant interferenceup to an H index of 1000 (approximatehemoglobin concentration: 1000 mg/dL)Icterus: No significant interference up toan | index 60 (approximate conjugatedand unconjugated bilirubin concentration:600 mg/L)High dose hook-effect: Using theprozone check, no false result without a flag was observed up to an albuminconcentration of 30000 mg/L.</td><td rowspan=1 colspan=1>Not specified for CSF.</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>Albumin in CSF:3 months to 4 year: &lt; 450 mg/L&gt; 4 years: 100 - 300 mg/L</td><td rowspan=1 colspan=1>Albumin in CSF: up to 350 mg/L</td></tr><tr><td rowspan=1 colspan=1>MethodComparisons</td><td rowspan=1 colspan=2>A comparison of the Roche Tina-quant Albumin Gen. 2 assay on the cobasc501 analyzer(x) with the nephelometric Albumin test gave the followingcorrelation:Passing Bablock                  Linear Regressiony = 1.000x - 8.75 mg/L        y = 0.991x + 0.301 mg/Lτ = 0.936                          r= 0.992n = 85Sample concentrations were between 115 and 2640 mg/L</td></tr></table>

Roche Diagnostics   
c/o Kathie Goodwin   
9115 Hague Road   
PO Box 50416   
Indianapolis, IN 46250-0416

Re: k101203 Trade Name: Tina-quant albumin gen 2 Regulation Number: 21 CFR $\ S 8 6 6 . 5 0 4 0$ EPY Regulation Name: Albumin immunological test system Regulatory Class: Class II Product Code: DCF Dated: September 9, 2010 Received: September 10, 2010

Dear Ms. Goodwin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976; the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). .

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket   
notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Gc

Courtney Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

k101203 510(k) Number (if known):

Device Name: Tina-quant Albumin Gen. 2

Indications for Use:

The Tina-quant Albumin Gen. 2 assay is an immunoturbidimetric assay intended for the quantitative determination of albumin in serum, plasma, urine, and CSF on Roche/Hitachi cobas c systems. Measurement of albumin aids in the diagnosis of kidney and intestinal diseases.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/2fddb61750abbcfb85c7819d1b67e8686a4a90eb74a244023e77836ae703c54e.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K101203